Can I Take Glycine With Lipitor (Atorvastatin)?

What Is Atorvastatin and How Is It Cleared?

Atorvastatin is an HMG-CoA reductase inhibitor prescribed for lowering LDL-C and reducing major adverse cardiovascular events. It is metabolized primarily by cytochrome P450 3A4 (CYP3A4) in the gut wall and liver, and it is also a substrate of the efflux transporter P-glycoprotein (P-gp) and the uptake transporter OATP1B1. Any compound that inhibits CYP3A4 or OATP1B1 can raise atorvastatin plasma concentrations and increase the risk of myopathy or rhabdomyolysis.

CYP3A4 and Why It Matters for Lipitor

CYP3A4 handles roughly 50% of all clinically used drugs. Strong inhibitors such as clarithromycin or itraconazole can increase atorvastatin AUC by 3- to 12-fold, raising myotoxicity risk substantially. The FDA label for atorvastatin explicitly lists co-administration with strong CYP3A4 inhibitors as a contraindication or dose-limiting situation depending on the inhibitor. Glycine has no published evidence of CYP3A4 inhibition or induction at any dose studied in humans.

OATP1B1 and Hepatic Uptake

OATP1B1 moves atorvastatin from portal blood into hepatocytes, where it exerts its pharmacological effect. Variants in the SLCO1B1 gene that reduce OATP1B1 function are the most common genetic cause of statin-associated myopathy. Drugs that compete for OATP1B1 (for example, gemfibrozil) can raise systemic statin exposure sharply. Glycine is not transported by OATP1B1 and does not appear in any pharmacokinetic inhibition studies targeting this transporter.

What Is Glycine and Why Do People Take It With Statins?

Glycine is the smallest amino acid and the most abundant amino acid in collagen. Adults synthesize roughly 3 g per day endogenously, but dietary and supplemental intake can raise plasma glycine meaningfully. Common supplemental doses range from 2 to 5 g taken at bedtime for sleep quality to higher doses of 15 to 60 g per day used in research settings for metabolic outcomes.

Sleep and Recovery Use

The most common reason patients combine glycine with a statin is bedtime sleep supplementation. A 2012 double-blind crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g glycine before sleep reduced subjective fatigue and improved polysomnographic sleep quality, including shorter sleep-onset latency. Atorvastatin is itself commonly dosed at bedtime, though unlike simvastatin it has a longer half-life (14 hours) that makes timing less pharmacologically critical. Taking both at the same time each evening is logistically convenient and does not create a drug-supplement conflict.

Collagen Synthesis Support

Glycine makes up approximately one-third of the amino acid residues in collagen. Athletes and older adults sometimes supplement glycine to support connective tissue repair. A 2019 randomized controlled trial (N=97) in the British Journal of Nutrition found that 5 g glycine plus 500 mg vitamin C improved functional outcomes related to collagen synthesis in tendons. Statins have a separate, debated association with tendinopathy; however, the available evidence does not suggest glycine worsens that risk and may theoretically be neutral or beneficial.

Metabolic and Glycemic Effects

Glycine has documented insulin-sensitizing properties. A 2016 systematic review in PLOS ONE (covering 8 clinical studies) found that glycine supplementation reduced fasting plasma glucose and improved insulin sensitivity in adults with metabolic syndrome. Atorvastatin, conversely, carries a small but statistically significant risk of new-onset type 2 diabetes: the JUPITER trial (N=17,802) reported a hazard ratio of 1.25 for new-onset diabetes with rosuvastatin vs. Placebo, and a 2019 meta-analysis of statin trials in The Lancet Diabetes and Endocrinology confirmed a similar signal across statins including atorvastatin, estimated at roughly one extra case of diabetes per 255 patients treated for 4 years. Glycine's glucose-lowering tendency may partially offset this pharmacodynamic effect, but that remains speculative rather than proven.

Pharmacokinetic Interaction Analysis

No head-to-head pharmacokinetic study has examined glycine plus atorvastatin in humans. The analysis below is based on glycine's known metabolic fate and atorvastatin's established interaction profile.

Hepatic Metabolism

Glycine is metabolized in the mitochondria via the glycine cleavage system, a four-enzyme complex that converts glycine to CO2, NH3, and a methylene unit transferred to tetrahydrofolate. This pathway does not involve CYP enzymes. A 2023 comprehensive review in Pharmacology and Therapeutics of amino acid-drug interactions found no amino acid acting as a meaningful CYP3A4 inhibitor at supplemental doses. Glycine is therefore not expected to alter atorvastatin AUC.

Protein Binding and Volume of Distribution

Atorvastatin is approximately 98% protein-bound. Displacement interactions occur when two compounds compete for the same albumin binding sites. Glycine binds plasma proteins weakly and at different sites; no displacement of atorvastatin is anticipated. At physiological plasma concentrations after a 3 g oral dose, glycine reaches roughly 150 to 200 µmol/L above baseline, far below the threshold that would saturate albumin binding capacity.

Renal Excretion

Atorvastatin undergoes negligible renal excretion (<2% unchanged in urine). Glycine is freely filtered and reabsorbed; it does not acidify or alkalinize urine in ways that would affect passive tubular reabsorption of atorvastatin.

Pharmacodynamic Interaction Analysis

Two potential pharmacodynamic overlaps deserve attention: effects on blood glucose and effects on skeletal muscle.

Glycemic Overlap

As noted above, statins carry a modest diabetogenic signal and glycine may carry a modest glucose-lowering signal. In a 2009 pilot trial published in Diabetes Care (N=60 adults with metabolic syndrome), 5 g glycine three times daily for 3 months reduced fasting glucose by 5.4 mg/dL (<0.01 by the original paper's reported P-value), reduced HOMA-IR, and lowered glycated hemoglobin by 0.2 percentage points. This is a mild effect. For most patients on atorvastatin with normal glucose tolerance, this interaction is clinically insignificant. Patients already on the borderline between normal glucose and pre-diabetes should monitor fasting glucose at their next routine lab visit and inform their prescriber.

Skeletal Muscle Effects

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of statin users in clinical practice, though randomized trials using blinded designs suggest a lower rate of true pharmacological myalgia, approximately 1 to 3% above placebo. The mechanism involves mitochondrial dysfunction and reduced coenzyme Q10 in muscle. Glycine has demonstrated mild cytoprotective effects on mitochondria in animal models. A 2018 study in Cell Metabolism (examining glycine's role in mitochondrial one-carbon metabolism) found that glycine supplementation supported mitochondrial function in aged mouse muscle. Whether that translates to reduced SAMS in humans taking atorvastatin is unknown; no clinical trial has tested this. Still, glycine does not appear to impair mitochondrial function in muscle and therefore does not raise SAMS risk.

What the Guidelines Say About Statin-Supplement Co-Administration

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, published in Circulation, advises clinicians to "review all concomitant medications and supplements before initiating statin therapy" due to the CYP3A4-dependent drug interaction potential of atorvastatin, simvastatin, and lovastatin. The guideline does not mention glycine specifically, which is expected since glycine carries no CYP3A4 interaction signal.

The European Atherosclerosis Society (EAS) 2019 Consensus Statement on SAMS, published in European Heart Journal, states that "supplements that inhibit CYP3A4 or OATP1B1 transporters can substantially increase statin plasma concentrations." By that criterion, glycine falls outside the concern category.

Neither the Natural Medicines Database (subscription resource) nor the Clinical Pharmacology database lists glycine as having an interaction with atorvastatin at any severity level.

A Practical Decision Framework for Patients Already Taking Both

The following framework is designed for clinical teams to apply during telehealth intake when a patient discloses glycine use alongside atorvastatin.

Step 1: Confirm Glycine Dose

Doses of 2 to 5 g per day carry minimal risk. Research doses of 15 g or higher per day are less common in supplement users but worth flagging. No toxicity ceiling for glycine has been established in healthy adults, though very high doses (>40 g/day for extended periods) can cause gastrointestinal discomfort and mild sedation. The FDA classifies glycine as Generally Recognized as Safe (GRAS) as a food additive.

Step 2: Check for Pre-Diabetes or Insulin Resistance

If the patient has a fasting glucose of 100 to 125 mg/dL or HbA1c of 5.7 to 6.4%, the pharmacodynamic picture becomes relevant. Paradoxically, glycine may slightly improve glucose in this range rather than worsen it. The main point is to document a baseline and check in at the next lab review.

Step 3: Check Current Atorvastatin Dose and Any Concurrent CYP3A4 Inhibitors

A patient on atorvastatin 80 mg with no other CYP3A4 inhibitors is already at the maximum daily dose. Adding glycine does not change the CYP3A4 picture, but this is an opportune moment to audit the full medication list. If the patient is also using azithromycin, fluconazole, or large amounts of grapefruit juice, those matter far more than glycine.

Step 4: Establish Monitoring Plan

Routine statin monitoring includes a lipid panel 4 to 12 weeks after initiation or dose change, and liver function tests if clinically indicated. Adding glycine does not require additional monitoring beyond what the atorvastatin label already recommends. If the patient has pre-diabetes, a fasting glucose or HbA1c check in 3 to 6 months is reasonable.

Step 5: Document and Continue

No dose-separation window is required. The patient may continue both simultaneously. Document the combination in the chart and reassess at annual medication review.

Specific Populations: When to Be More Cautious

Patients With Chronic Kidney Disease

Glycine is cleared renally as well as metabolized in the liver. Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² may accumulate glycine at high supplemental doses. Atorvastatin itself does not require dose adjustment for renal impairment, but CKD patients on atorvastatin often take multiple other medications with genuine CYP3A4 interactions. The glycine-atorvastatin combination is still not the concern; the concurrent drug burden is.

Patients With Hepatic Impairment

Atorvastatin is contraindicated in active liver disease. Glycine is processed hepatically via the glycine cleavage system; in severe hepatic impairment, glycine might accumulate since that cleavage pathway is impaired. Combining high-dose glycine with atorvastatin in a patient with Child-Pugh B or C cirrhosis is not recommended, primarily because atorvastatin itself should generally be avoided in that context.

Pregnant or Breastfeeding Patients

Statins including atorvastatin are contraindicated in pregnancy. Glycine at dietary amounts is safe in pregnancy (it is an endogenously produced amino acid), but the clinical question is moot if atorvastatin is already appropriately discontinued.

Older Adults Over 75

SAMS risk increases with age, lower body weight, and multimorbidity. The AHA/ACC guideline notes that "adults >75 years with established ASCVD should have a clinician-patient discussion before initiating high-intensity statin therapy." For this group, glycine is still not the interaction concern, but the same intake assessment is an opening to review the entire supplement list.

What the Evidence Does Not Yet Tell Us

No randomized controlled trial has specifically enrolled adults on atorvastatin, randomized them to glycine or placebo, and measured atorvastatin AUC, LDL-C lowering, or SAMS incidence as primary outcomes. The absence of such a trial means the safety conclusion here rests on mechanistic reasoning and indirect evidence rather than a direct efficacy-safety study. That is a limitation of the current literature, not a unique problem with this supplement. The same gap exists for dozens of commonly used supplements taken alongside statins.

A 2021 systematic review in the Journal of the American Heart Association that assessed 44 dietary supplements for cardiovascular effect found glycine among the supplements with insufficient trial-level evidence to make strong clinical recommendations for or against cardiovascular benefit. The review did not identify a safety signal.

Ongoing research into glycine's role in one-carbon metabolism and cardiovascular risk may eventually produce direct statin-relevant data. Until then, the current weight of mechanistic evidence does not justify restricting glycine use in atorvastatin-treated patients.

Drug Interactions That Actually Matter for Atorvastatin

For context, the interactions that genuinely require prescriber attention with atorvastatin include: cyclosporine (raises AUC by up to 8-fold), clarithromycin (raises AUC approximately 4.4-fold), itraconazole (raises AUC approximately 3-fold), and the combination of lopinavir/ritonavir (raises AUC approximately 5.9-fold). Fibrates, particularly gemfibrozil, raise the risk of myopathy via OATP1B1 inhibition. Red yeast rice, which contains monacolin K (a natural lovastatin analog), effectively doubles statin exposure in patients already prescribed atorvastatin and warrants a direct clinical conversation. Glycine does not belong in this high-concern category.